SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
August 27, 2024 08:00 ET
|
Scynexis
JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Triyam Recognized on Inc. 5000 List for the Fourth Consecutive Year
August 15, 2024 09:00 ET
|
Access Information Management Shared Services, LLC
Company ranking leveled up 999 spots on this highlighted list of America’s Fastest-Growing Private Companies
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024 16:30 ET
|
Scynexis
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to...
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
July 23, 2024 07:00 ET
|
Scynexis
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
AvePoint Named to Inc.’s Annual List of Best Workplaces for 2024
June 18, 2024 08:45 ET
|
AvePoint, Inc.
JERSEY CITY, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT), the global leader in robust data management and data governance, today announced it has been named to Inc.’s annual Best...
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024 16:30 ET
|
Scynexis
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
April 30, 2024 16:05 ET
|
Scynexis
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 09, 2024 16:05 ET
|
Scynexis
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List
April 09, 2024 09:15 ET
|
Lily AI
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List.
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 16:01 ET
|
Scynexis
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study...